MedPath

Postoperative Opioid and Respiratory Depression in Opioid Naive and Chronic Opioid Patients

Completed
Conditions
Medical Complication
Registration Number
NCT06227208
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

Aim: To describe the duration of desaturation and bradypnea in postoperative opioid-naïve and chronic opioid patients. Patients: 691 patients included from two previous WARD (Wireless Assessment of Respiratory and circulatory Distress) projects. Outcome: Respiratory deviations four hours after opioid administration

Detailed Description

Aim: To describe the duration of desaturation and bradypnea in postoperative opioid-naïve and chronic opioid patients within the first four hours following opioid administration in addition to the chronic dose, using a continuously wireless monitoring system.

Patients: 691 patients included from two previous WARD (Wireless Assessment of Respiratory and circulatory Distress) projects. Continuous wireless monitoring data of peripheral tissue oxygenation (SpO2) and respiratory rate (RR) was conducted in postoperative patients. Data were stratified into opioid-naïve and chronic opioid patients, based on their preoperative opioid history. Patients who did not receive opioids postoperatively were served as the control group. Data was evaluated one hour before and four hours after opioid administration. The primary outcome was the cumulative duration of SpO2 \<88%.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
691
Inclusion Criteria
  • Patients from studies WARD Surgery Observational [gov: NCT03491137]
  • The control group from WARD Surgery Randomized Controlled Trial [gov: NCT04640415]
Exclusion Criteria
  • Less than 30 minutes of continuous monitoring data within the 60-minute window prior to opioid administration
  • Less than 120 minutes (<50% of theoretical maximum) of monitoring data available during the four-hour observation period
  • Patients who received transdermal fentanyl as postoperative opioid
  • Patients with a baseline saturation or respiratory rate below the prespecified thresholds
  • Patients with a BMI of ≥40 or diagnosed with COPD were excluded in the analysis of SpO2 <92%

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
SpO2 <88% in the four hours following opioid administrationfour hours following opioid administration
Secondary Outcome Measures
NameTimeMethod
Respiratory deviations four hours after opioid administrationfour hours following opioid administration

SpO2 \<92%, \<88 %, \<85%, \<80% and respiratory rate ≤11 min-1, ≤8 min-1, ≤5 min-1

Trial Locations

Locations (2)

Rigshospitalet

🇩🇰

Copenhagen, Denmark

Bispebjerg Hospital

🇩🇰

Copenhagen, Denmark

Rigshospitalet
🇩🇰Copenhagen, Denmark

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.